Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation

• Published in: Cell death and differentiation Vol. 23; no. 6; pp. 938 - 951
• Main Authors: Garg, A D, Romano, E, Rufo, N, Agostinis, P
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.06.2016; Nature Publishing Group
• Subjects: 631/250/21/1293; Alarmins - metabolism; Antigens; Apoptosis; Biochemistry; Biomedical and Life Sciences; Cancer; CD47 Antigen - metabolism; Cell Biology; Cell Cycle Analysis; Cell death; Cytotoxicity; Ferroptosis; HSP90 Heat-Shock Proteins - metabolism; Humans; Immunology; Immunotherapy; Kinases; Life Sciences; Neoplasms - immunology; Neoplasms - pathology; Neoplasms - therapy; Phagocytosis - immunology; Phagocytosis - physiology; Physiology; Proteins; Receptors, Immunologic - metabolism; Review; Signal Transduction; Stem Cells; Belgium
• ISSN: 1350-9047; 1476-5403
• DOI: 10.1038/cdd.2016.5

Phagocytosis of dying cells is a major homeostatic process that represents the final stage of cell death in a tissue context. Under basal conditions, in a diseased tissue (such as cancer) or after treatment with cytotoxic therapies (such as anticancer therapies), phagocytosis has a major role in avoiding toxic accumulation of cellular corpses. Recognition and phagocytosis of dying cancer cells dictate the eventual immunological consequences (i.e., tolerogenic, inflammatory or immunogenic) depending on a series of factors, including the type of ‘eat me’ signals. Homeostatic clearance of dying cancer cells (i.e., tolerogenic phagocytosis) tends to facilitate pro-tumorigenic processes and actively suppress antitumour immunity. Conversely, cancer cells killed by immunogenic anticancer therapies may stimulate non-homeostatic clearance by antigen-presenting cells and drive cancer antigen-directed immunity. On the other hand, (a general) inflammatory clearance of dying cancer cells could have pro-tumorigenic or antitumorigenic consequences depending on the context. Interestingly, the immunosuppressive consequences that accompany tolerogenic phagocytosis can be reversed through immune-checkpoint therapies. In the present review, we discuss the pivotal role of phagocytosis in regulating responses to anticancer therapy. We give particular attention to the role of phagocytosis following treatment with immunogenic or immune-checkpoint therapies, the clinical prognostic and predictive significance of phagocytic signals for cancer patients and the therapeutic strategies that can be employed for direct targeting of phagocytic determinants.